TIDMIXI
IXICO plc
29 July 2016
IXICO Technologies plc: Web-Based Technology Improves Paediatric
ADHD Care and Patient Outcomes
London, UK, 29 July 2016: IXICO plc (Ticker: IXI) ('IXICO' or
the 'Company'), the brain health company, is pleased to note a
press release from Cincinnati Children's a non-profit, paediatric,
academic medical centre. This release notes the publication of
positive result in a peer-reviewed journal of a multi-institutional
study examining the use of a new web-based software program to help
to reduce ADHD behavioural symptoms in children. The web-based
digital healthcare platform has been licensed to IXICO and is now
available as a clinical decision support tool in the US from
www.mehealthcom. The full text of the press release is reproduced
below.
Web-Based Technology Improves Pediatric ADHD Care and Patient
Outcomes
CINCINNATI 26 July - As cases of ADHD continue to rise among
U.S. children, pediatricians at busy community practices are
getting a much-needed assist from a web-based technology to improve
the quality of ADHD care and improve patient outcomes.
According to a multi-institutional study published online July
26 in Pediatrics, a new web-based software program is helping
reduce ADHD behavioral symptoms in children receiving care at
community pediatric practices by coordinating care and ensuring
patients get the most effective ADHD medication for their care.
This is important for children with ADHD who rely on extremely
busy community based pediatric practices where ADHD care is often
poor - especially in the areas of medication management and
monitoring, according to Jeffery Epstein, PhD, the study's
principal investigator and director of the Center for ADHD at
Cincinnati Children's Hospital Medical Center.
"Our data show the software not only helped improve the quality
of medication care received by children treated at community based
pediatric practices, but it also improved treatment outcomes for
these children," Epstein said. "As a result of the improved quality
of ADHD care, children treated by pediatricians using this new
technology had significantly less ADHD symptoms than children
treated by pediatricians who were not given access to this
web-based technology."
The ADHD care quality improvement (QI) software was developed by
Epstein and research colleagues at Cincinnati Children's. The
American Academy of Pediatrics (AAP) has selected this QI software
for dissemination to community based pediatrics practices in five
states.
Available through a web-based portal, the software helps
community practices collect, score and interpret reports from
parents and teachers regarding children's ADHD symptoms - allowing
pediatricians to better gauge whether medications are working with
their patients.
Providers at community practices can customize the schedule of
collection of these ratings for each patient. When ratings are
completed, automated algorithms score and interpret data.
Physicians then receive text and graphs charting patient response
to medication and other related information, allowing them to
determine if ADHD symptoms are improving in response to the
prescribed medication and dosage.
The current study involved a randomized clinical trial
coordinated through Cincinnati Children's and Nationwide Children's
Hospital in Columbus, Ohio.
The trial was conducted at 50 community based pediatric
practices involving 199 providers. The providers were randomized to
either provide ADHD care using the technology assisted QI
intervention or without the intervention.
A total of 373 children with ADHD included in study were
prescribed ADHD medications for their condition (165 children at
practices using the software intervention and 208 at control
practices not using the software). A standard rating scale (the
Vanderbilt ADHD Parent Rating Scale) was used before and following
treatment to rate ADHD symptoms.
Medicated children cared for at control practices (which did not
use the software) experienced an average 10.19-point reduction on
the parent-rated scale of symptoms. Children at pediatric practices
using the technology based intervention experienced an average
symptom reduction of 13.19 points.
Compared to children at practices not using the technology,
children cared for practices with the technology had significantly
more treatment contacts with clinical staff and a greater number of
parent and teacher ratings to monitoring the effectiveness of
medications. Researchers said that treatment effectiveness and
outcomes were more quickly assessed at practices using the
software.
Researchers report that the study's community based nature led
to some limitations involving the consistency of data collection -
making it difficult to generalize the data to all community
practices and providers, according to the authors. The study also
focused only on the primary outcome of ADHD symptoms. It did not
evaluate functional impairments (such as school performance), which
are often why families seek treatment for ADHD.
Epstein said that future goals for this intervention include
extending the software's use to facilitate behavioral treatment.
Researchers also want to explore strategies for expanding use of
the technology to include all patients with ADHD (including
integrating its use with electronic health records, pay for
performance initiatives, etc.) and patients with other pediatric
mental disorders.
Funding support came from: This research was supported by grant
#R01 MH083665 from the National Institute of Mental Health and
grant #UL1 TR000077 from the National Center for Advancing
Translational Sciences of the National Institutes of Health. Drs.
Epstein and Brinkman were supported by grant #s K24MH064478 and
K23MH083027 from the National Institute of Mental Health,
respectively.
The software has been licensed by Cincinnati Children's to IXICO
Technologies Inc. for further development and transition into the
patient care environment.
About Cincinnati Children's
Cincinnati Children's, a non-profit, pediatric, academic medical
center established in 1883, is internationally recognized for
improving child health and transforming delivery of care through
fully integrated, globally recognized research, education and
innovation. It is one of the top three recipients of pediatric
research grants from the National Institutes of Health, ranked
third in the nation among all Honor Roll hospitals in U.S. News and
World Report's Best Children's Hospitals, and a research and
teaching affiliate of the University of Cincinnati's College of
Medicine. Its patient population includes the eight-county primary
service area covering parts of Ohio, Kentucky and Indiana. A
destination for children with complex medical conditions, it also
served patients from all 50 states and nearly 70 countries during
the past year. Additional information can be found at
www.cincinnatichildrens.org. Connect on the Cincinnati Children's
blog, via Facebook and on Twitter.
Enquiries:
IXICO plc +44 20 3763 7499
Derek Hill, CEO
Susan Lowther, CFO
Peel Hunt LLP (Nominated
Adviser and Broker)
James Steel / Oliver Jackson +44 20 7418 8900
Daniel Stewart & Company
(Joint Broker)
Martin Lampshire / David
Coffman +44 207 776 6550
FTI Consulting Limited
(Investor Relations)
Simon Conway / Mo Noonan
/ Matthew Moss +44 20 3727 1000
Notes to Editors
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, behavioural health, child
and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEANXNAFNKEEF
(END) Dow Jones Newswires
July 29, 2016 05:25 ET (09:25 GMT)
Grafico Azioni Phytopharm (LSE:PYM)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Phytopharm (LSE:PYM)
Storico
Da Dic 2023 a Dic 2024
